Comparative Study of Carvedilol Monotherapy Versus Combination Therapy With Endoscopic Variceal Ligation (EVL) for Primary Prophylaxis of Variceal Bleeding in Patients With Hepatocellular Carcinoma With High-Risk Esophageal Varices

NANot yet recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

February 20, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Carvedilol Tablets

Non-selective beta blocker (Carvedilol 3.125 mg BD for 3 days followed by 6.25 mg BD , maximum dose would be 12.5 mg BD , same shall be switch to maximum tolerable dose if Systolic BP\< 90 , H,R\<55)

PROCEDURE

Endoscopic Variceal Ligation

EVL every 3 weeks till eradication of varices followed by every 3 months.

Trial Locations (1)

110070

Institute of Liver & Biliary Sciences (ILBS), New Delhi

All Listed Sponsors
lead

Institute of Liver and Biliary Sciences, India

OTHER

NCT06836778 - Comparative Study of Carvedilol Monotherapy Versus Combination Therapy With Endoscopic Variceal Ligation (EVL) for Primary Prophylaxis of Variceal Bleeding in Patients With Hepatocellular Carcinoma With High-Risk Esophageal Varices | Biotech Hunter | Biotech Hunter